The ulcerative colitis market was valued at USD 7.49 Billion in 2024 driven by the increasing demand for advanced biologics and immunomodulators across the 8 major markets. It is expected to grow at a CAGR of 3.75% during the forecast period of 2025-2034 and attain a market value of USD 10.82 Billion by 2034.
Ulcerative Colitis Market Overview
The market is expanding primarily due to the rising number of people suffering from this chronic inflammatory bowel disease, which affects millions globally. A key driver for this expansion is the rising need for sophisticated biologics and immunomodulators. Additionally, innovative oral therapies that provide corticosteroid-free remission are gaining traction. Trends such as regulatory approvals for new treatments and strategic mergers within the industry, signal a promising expansion of the market. These developments reflect a collective effort to enhance treatment options, ultimately striving to improve the quality of life for patients suffering from ulcerative colitis globally.
Ulcerative Colitis Market Growth Drivers
Rising Prevalence of Ulcerative Colitis Drives Market Growth
The escalating incidence of ulcerative colitis has become a pivotal factor influencing the market growth. In 2023, the global prevalence was reported at approximately 5 million cases, indicating a significant increase in incidence rates across various regions. This is fostering demand for advanced treatment options, accelerating the development and market adoption of biologics and immunomodulators to address this growing healthcare need.
Ulcerative Colitis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Rise in Strategic Mergers and Acquisitions to Affect the Market
Several market players are stepping forward to enhance their ulcerative colitis care portfolio propelled by the surge in strategic mergers and acquisitions. For instance, in June 2023, Merck & Co. completed an agreement to purchase Prometheus Biosciences for approximately USD 10.8 billion. This acquisition allows Prometheus Biosciences to fully harness the potential of PRA023, an advanced candidate in late-stage development designed to address conditions such as ulcerative colitis, Crohn's disease, and various autoimmune disorders. Such strategic mergers and acquisitions are likely to enhance innovation and competitive dynamics within the market.
Surge in Regulatory Approvals to Boost Ulcerative Colitis Market Value
The surge in regulatory approvals is significantly impacting the market dynamics positively. For, instance in December 2024, Celltrion received FDA approval for STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in both adults and pediatric patients. The approval, based on a phase III study demonstrating similar safety and efficacy to the reference product, marks a strategic expansion of Celltrion's immunology portfolio, thus supporting overall market growth by increasing treatment options and accessibility.
Advancements in Clinical Trials to Meet Rising Ulcerative Colitis Market Demand
Advancements in clinical trials are significantly driving innovation within the market, representing a pivotal shift towards more effective therapeutic solutions. For instance, in December 2024, Accropeutics Inc. received FDA clearance for its IND application for AC-101, a RIPK2 inhibitor, which enabled pivotal Phase II trials to evaluate its safety and efficacy in treating moderate-to-severe ulcerative colitis. This proactive approach, alongside ongoing studies in China, underscores the industry's commitment to addressing unmet medical needs and enhancing patient outcomes, thereby supporting growth and investment in the ulcerative colitis market.
Growing Awareness Campaigns to Boost Ulcerative Colitis Market Size
The increase in awareness campaigns is significantly contributing to the market expansion. These initiatives are driving public knowledge about the symptoms of ulcerative colitis, such as stomach pain, and fatigue, which is leading to earlier diagnoses and better treatment outcomes. For instance, in March 2023, the Scottish Government launched a comprehensive campaign aimed at raising awareness of Chron’s disease and ulcerative colitis. The campaign, supported by research from Crohn’s and Colitis UK, encouraged individuals to recognize symptoms early and seek medical advice. Thus, it directly supported the demand for innovative treatment solutions in the market. This rise in public awareness is set to fuel the market’s growth by encouraging more individuals to seek diagnosis and care for ulcerative colitis.
Ulcerative Colitis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook